Last reviewed · How we verify

Lorcam (LORNOXICAM)

discontinued Small molecule

Lorcam works by blocking the COX-2 enzyme, which reduces the production of prostaglandins that cause pain and inflammation.

Lorcam, also known as Lornoxicam, is a small molecule nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. It is used to treat pain, but its target is unknown. Lorcam is not FDA approved, and its commercial status is unclear. Key safety considerations include its low bioavailability of 1%, which may impact its efficacy. As a nonsteroidal anti-inflammatory drug, Lorcam works by inhibiting the enzyme COX-2, which is involved in the production of prostaglandins that cause pain and inflammation.

At a glance

Generic nameLORNOXICAM
Drug classlornoxicam
ModalitySmall molecule
Therapeutic areaPain
Phasediscontinued

Mechanism of action

Imagine your body has a factory that produces chemicals called prostaglandins, which can cause pain and swelling. Lorcam blocks the machine that makes these chemicals, so the pain and swelling go away. This helps to relieve pain and reduce inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: